LU82026A1 - Preparation pharmaceutique comprenant un glycoside cardiaque ayant un revetement de polymere - Google Patents

Preparation pharmaceutique comprenant un glycoside cardiaque ayant un revetement de polymere Download PDF

Info

Publication number: LU82026A1
Authority: LU; Luxembourg
Prior art keywords: layer; pharmaceutical preparation; cardiac glycoside; soluble; solution
Prior art date: 1978-12-22

Application number

LU82026A

Other languages

English (en)

French (fr)

Inventor

C Appelgren

C Bogentoft

J Sjoegren

Original Assignee

Haessle Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-12-22

Filing date

1979-12-21

Publication date

1980-07-21

1979-12-21 Application filed by Haessle Ab filed Critical Haessle Ab

1980-07-21 Publication of LU82026A1 publication Critical patent/LU82026A1/fr

Links

229940097217 cardiac glycoside Drugs 0.000 title claims abstract description 25
239000002368 cardiac glycoside Substances 0.000 title claims abstract description 25
229930002534 steroid glycoside Natural products 0.000 title claims abstract description 25
239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 22
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 title claims abstract description 21
229920000642 polymer Polymers 0.000 title claims abstract description 20
239000011248 coating agent Substances 0.000 title claims description 9
238000000576 coating method Methods 0.000 title claims description 9
238000002360 preparation method Methods 0.000 claims abstract description 31
238000000034 method Methods 0.000 claims abstract description 26
238000004519 manufacturing process Methods 0.000 claims abstract description 5
239000007787 solid Substances 0.000 claims abstract description 4
230000008569 process Effects 0.000 claims description 9
239000000463 material Substances 0.000 claims description 7
238000005507 spraying Methods 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 5
125000000129 anionic group Chemical group 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 4
208000019622 heart disease Diseases 0.000 claims description 4
229920003169 water-soluble polymer Polymers 0.000 claims description 4
208000020446 Cardiac disease Diseases 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 2
229930182470 glycoside Natural products 0.000 abstract description 11
150000002338 glycosides Chemical class 0.000 abstract description 10
210000004051 gastric juice Anatomy 0.000 abstract description 9
235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 7
230000000968 intestinal effect Effects 0.000 abstract description 5
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 30
LTMHDMANZUZIPE-UHFFFAOYSA-N 3-[3-[5-[5-(4,5-dihydroxy-6-methyloxan-2-yl)oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one Chemical compound C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 24
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 23
229960005156 digoxin Drugs 0.000 description 23
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 23
239000000243 solution Substances 0.000 description 19
229960000541 cetyl alcohol Drugs 0.000 description 11
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 11
229940073584 methylene chloride Drugs 0.000 description 10
150000001875 compounds Chemical class 0.000 description 9
229920001223 polyethylene glycol Polymers 0.000 description 8
235000000346 sugar Nutrition 0.000 description 7
210000002700 urine Anatomy 0.000 description 7
239000002202 Polyethylene glycol Substances 0.000 description 6
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 5
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
238000013268 sustained release Methods 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
241000208011 Digitalis Species 0.000 description 4
238000000354 decomposition reaction Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
125000000325 methylidene group Chemical class [H]C([H])=* 0.000 description 4
239000006174 pH buffer Substances 0.000 description 4
150000008143 steroidal glycosides Chemical class 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229960000648 digitoxin Drugs 0.000 description 3
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 3
239000002904 solvent Substances 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
-1 Carbohydrate glycosides Chemical class 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
229920003136 Eudragit® L polymer Polymers 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 2
JAYAGJDXJIDEKI-UHFFFAOYSA-N Lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC(C)=O)C1OC1OC(CO)C(O)C(O)C1O JAYAGJDXJIDEKI-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
239000008118 PEG 6000 Substances 0.000 description 2
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
MYEJFUXQJGHEQK-ALRJYLEOSA-N Proscillaridin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C=C2CC[C@H]3[C@@]4(O)CC[C@H](C5=COC(=O)C=C5)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 MYEJFUXQJGHEQK-ALRJYLEOSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
229920006318 anionic polymer Polymers 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
206010003119 arrhythmia Diseases 0.000 description 2
230000006793 arrhythmia Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
238000010586 diagram Methods 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229960002614 lanatoside c Drugs 0.000 description 2
239000002609 medium Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
PESZCXUNMKAYME-UHFFFAOYSA-N Citroflex A-4 Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)C(C(C)=O)C(=O)OCCCC PESZCXUNMKAYME-UHFFFAOYSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
JNOJRRIGRCMXLQ-UHFFFAOYSA-N PPPPPPPPP Chemical compound PPPPPPPPP JNOJRRIGRCMXLQ-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
JDYLJSDIEBHXPO-ALNZGLKXSA-N [(2r,3r,4s,6r)-3-[(2s,4s,5r,6r)-4-acetyloxy-5-[(2s,4s,5r,6r)-4,5-diacetyloxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-[[(3s,5r,8r,9s,10s,13r,14s,16s,17r)-16-acetyloxy-14-hydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17 Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(C[C@@H]([C@@H]([C@@]4(C)CC3)C=3COC(=O)C=3)OC(C)=O)O)CC2)(C)CC1)[C@H]1C[C@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](C)O1 JDYLJSDIEBHXPO-ALNZGLKXSA-N 0.000 description 1
GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
229960003304 acetyldigoxin Drugs 0.000 description 1
HWKJSYYYURVNQU-DXJNJSHLSA-N acetyldigoxin Chemical compound C1[C@H](OC(C)=O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O HWKJSYYYURVNQU-DXJNJSHLSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
ACLJAFRNPZVVIW-ADFGDECNSA-N actodigin Chemical compound O([C@@H]1C[C@H]2CC[C@@H]3[C@@H]([C@]2(CC1)C)CC[C@]1([C@]3(O)CC[C@@H]1C=1C(OCC=1)=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ACLJAFRNPZVVIW-ADFGDECNSA-N 0.000 description 1
238000007792 addition Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
MGVYFNHJWXJYBE-UHFFFAOYSA-N alpha-Acetyl-digoxin Natural products CC1OC(CC(O)C1O)OC2C(O)CC(OC3C(C)OC(CC3OC(=O)C)OC4CCC5(C)C(CCC6C5CCC7(C)C(C(O)CC67O)C8=CC(=O)OC8)C4)OC2C MGVYFNHJWXJYBE-UHFFFAOYSA-N 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229940082657 digitalis glycosides Drugs 0.000 description 1
XZTUSOXSLKTKJQ-CESUGQOBSA-N digitoxigenin Chemical group C1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)CC[C@@]32C)=CC(=O)OC1 XZTUSOXSLKTKJQ-CESUGQOBSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960003746 metildigoxin Drugs 0.000 description 1
IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
125000005498 phthalate group Chemical class 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000007873 sieving Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU82026A 1978-12-22 1979-12-21 Preparation pharmaceutique comprenant un glycoside cardiaque ayant un revetement de polymere LU82026A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE7813246		1978-12-22
SE7813246A SE7813246L (sv)	1978-12-22	1978-12-22	Fast farmaceutisk beredning innehallande kroppar med flera ytskikt

Publications (1)

Publication Number	Publication Date
LU82026A1 true LU82026A1 (fr)	1980-07-21

Family

ID=20336689

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU82026A LU82026A1 (fr)	1978-12-22	1979-12-21	Preparation pharmaceutique comprenant un glycoside cardiaque ayant un revetement de polymere

Country Status (20)

Country	Link
US (1)	US4263273A (no)
EP (1)	EP0013262B1 (no)
JP (1)	JPS5587716A (no)
AT (1)	ATE4370T1 (no)
AU (1)	AU531280B2 (no)
BE (1)	BE880797A (no)
CA (1)	CA1130211A (no)
CH (1)	CH641357A5 (no)
DE (1)	DE2966036D1 (no)
DK (1)	DK542279A (no)
ES (1)	ES487181A0 (no)
FI (1)	FI794007A7 (no)
GR (1)	GR69819B (no)
IE (1)	IE48891B1 (no)
LU (1)	LU82026A1 (no)
NO (1)	NO152726C (no)
NZ (1)	NZ192441A (no)
PT (1)	PT70619A (no)
SE (1)	SE7813246L (no)
ZA (1)	ZA796684B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1144911B (it) *	1981-03-19	1986-10-29	Pharmatec Spa	Composizione farmaceutica a rilascio controllato contenente ibuprofen
EP0064485B1 (en) *	1981-04-27	1985-07-24	Aktiebolaget Hässle	New pharmaceutical preparation
DK150008C (da) *	1981-11-20	1987-05-25	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
DK151608C (da) *	1982-08-13	1988-06-20	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
US4578075A (en) *	1982-12-20	1986-03-25	Alza Corporation	Delivery system housing a plurality of delivery devices
US4681583A (en) *	1982-12-20	1987-07-21	Alza Corporation	System for dispersing drug in biological environment
US4773907A (en) *	1982-12-20	1988-09-27	Alza Corporation	Primary delivery system comprising secondary dosage form
IE56459B1 (en) *	1983-12-21	1991-08-14	Elan Corp Ltd	Controlled absorption pharmaceutical formulation
US4894240A (en) *	1983-12-22	1990-01-16	Elan Corporation Plc	Controlled absorption diltiazem formulation for once-daily administration
US4917899A (en) *	1983-12-22	1990-04-17	Elan Corporation Plc	Controlled absorption diltiazem formulation
IE56999B1 (en) *	1983-12-22	1992-03-11	Elan Corp Plc	Pharmaceutical formulation
DE3586600T2 (de)	1984-02-10	1993-02-18	Benzon Pharma As	Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend.
DK62184D0 (da) *	1984-02-10	1984-02-10	Benzon As Alfred	Diffusionsovertrukket polydepotpraeparat
GB8414220D0 (en) *	1984-06-04	1984-07-11	Sterwin Ag	Medicaments in unit dose form
US4656831A (en) *	1985-05-14	1987-04-14	Chamberlain Manufacturing Corporation	Apparatus and method of recovering water from engine exhaust gases
US4861598A (en) *	1986-07-18	1989-08-29	Euroceltique, S.A.	Controlled release bases for pharmaceuticals
US4883666A (en) *	1987-04-29	1989-11-28	Massachusetts Institute Of Technology	Controlled drug delivery system for treatment of neural disorders
US5601835A (en) *	1987-04-29	1997-02-11	Massachusetts Institute Of Technology	Polymeric device for controlled drug delivery to the CNS
US5912017A (en) *	1987-05-01	1999-06-15	Massachusetts Institute Of Technology	Multiwall polymeric microspheres
US5985354A (en)	1995-06-07	1999-11-16	Brown University Research Foundation	Preparation of multiwall polymeric microcapsules from hydrophilic polymers
JPH0774151B2 (ja) *	1987-10-12	1995-08-09	三井東圧化学株式会社	薬物の好ましくない官能的性質を隠蔽した散剤の製造方法
JPH01165520A (ja) *	1987-12-23	1989-06-29	Shin Etsu Chem Co Ltd	持続性製剤およびその製造方法
US4925675A (en) *	1988-08-19	1990-05-15	Himedics, Inc.	Erythromycin microencapsulated granules
US4925674A (en) *	1988-08-25	1990-05-15	Himedics, Inc.	Amoxicillin microencapsulated granules
US4966770A (en) *	1989-07-26	1990-10-30	Himedics, Inc.	Prednisone microencapsulated granules
PH27186A (en) *	1989-09-07	1993-04-16	Ciba Geigy Ag	Double-coated granules of disodium pamidronate
SE8903914D0 (sv)	1989-11-22	1989-11-22	Draco Ab	Oral composition for the treatment of inflammatory bowel diseases
FR2663222A1 (fr) *	1990-06-13	1991-12-20	Medgenix Group Sa	Microcapsule de liquide huileux.
US5288505A (en) *	1991-06-26	1994-02-22	Galephar P.R., Inc., Ltd.	Extended release form of diltiazem
US5167964A (en) *	1992-02-14	1992-12-01	Warner-Lambert Company	Semi-enteric drug delivery systems and methods for preparing same
US7108866B1 (en)	1999-12-10	2006-09-19	Biovall Laboratories International Srl	Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) *	1999-12-10	2006-07-13	Biovail Laboratories International S.R.L.	Chronotherapeutic diltiazem formulations and the administration thereof
US20040082521A1 (en) *	2002-03-29	2004-04-29	Azaya Therapeutics Inc.	Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2455790A (en) *	1945-06-09	1948-12-07	Eastman Kodak Co	Enteric coatings
CH283585A (de) *	1950-03-15	1952-06-15	Hoffmann La Roche	Zur Herstellung von Tablettenüberzügen geeignetes Gemisch.
US2698822A (en) *	1951-04-28	1955-01-04	Fougera & Co Inc E	Cardiac glycoside buccal composition
US2881085A (en) *	1953-11-09	1959-04-07	Abbott Lab	Thin film coating for tablets and the like
US2853420A (en) *	1956-01-25	1958-09-23	Lowey Hans	Ethyl cellulose coatings for shaped medicinal preparations
US2921883A (en) *	1957-05-03	1960-01-19	Smith Kline French Lab	Novel coating material for medicaments
US2928770A (en) *	1958-11-28	1960-03-15	Frank M Bardani	Sustained action pill
IT629516A (no) *	1959-04-30
NL270408A (no) *	1960-10-20
DE1228757B (de) *	1962-06-28	1966-11-17	Haessle Ab	Verfahren zur Herstellung eines in Wasser und Magensaft rasch zerfallenden UEberzuges auf festen Arzneiformen
US3247066A (en) *	1962-09-12	1966-04-19	Parke Davis & Co	Controlled release dosage form containing water-swellable beadlet
US3325365A (en) *	1963-04-02	1967-06-13	Ciba Geigy Corp	Enteric composition for tablet compression coating
NL297631A (no) *	1963-06-03
US3400185A (en) *	1965-04-08	1968-09-03	Bristol Myers Co	Agglomeration of smaller pharmaceutical particles into larger microspherules and enteic-coating thereof
US3538214A (en) *	1969-04-22	1970-11-03	Merck & Co Inc	Controlled release medicinal tablets
DE2010416B2 (de) *	1970-03-05	1979-03-29	Hoechst Ag, 6000 Frankfurt	Oral anwendbare Arzneiform mit Retardwirkung
DE2031871C3 (de) *	1970-06-27	1974-06-27	Roehm Gmbh, 6100 Darmstadt	Überzugsmasse für Arzneiformen
US3954959A (en) *	1973-03-28	1976-05-04	A/S Alfred Benzon	Oral drug preparations
IL42166A (en) *	1973-05-02	1976-01-30	Res Prod Rehovot Ltd	Drug releasing preparation
DE2336218C3 (de) *	1973-07-17	1985-11-14	Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz	Orale Arzneiform
US3965255A (en) *	1974-05-01	1976-06-22	E. E. Eljim Ecology Ltd.	Controlled drug releasing preparations
US4151273A (en) *	1974-10-31	1979-04-24	The Regents Of The University Of California	Increasing the absorption rate of insoluble drugs
SE418247B (sv) *	1975-11-17	1981-05-18	Haessle Ab	Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
FR2313915A1 (fr) *	1976-01-26	1977-01-07	Corneille Gilbert	Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme
US4202888A (en) *	1976-07-12	1980-05-13	Kali-Chemie Pharma Gmbh.	Readily enterally absorbable pharmaceutical compositions of cardiac glycosides and preparation thereof
US4147768A (en) *	1976-09-13	1979-04-03	Interx Research Corporation	Enteric coated digoxin and therapeutic use thereof

1978
- 1978-12-22 SE SE7813246A patent/SE7813246L/xx not_active Application Discontinuation
1979
- 1979-12-10 ZA ZA00796684A patent/ZA796684B/xx unknown
- 1979-12-13 EP EP79850110A patent/EP0013262B1/en not_active Expired
- 1979-12-13 DE DE7979850110T patent/DE2966036D1/de not_active Expired
- 1979-12-13 AT AT79850110T patent/ATE4370T1/de not_active IP Right Cessation
- 1979-12-17 US US06/104,689 patent/US4263273A/en not_active Expired - Lifetime
- 1979-12-17 CA CA342,037A patent/CA1130211A/en not_active Expired
- 1979-12-18 AU AU53963/79A patent/AU531280B2/en not_active Ceased
- 1979-12-18 NZ NZ192441A patent/NZ192441A/en unknown
- 1979-12-18 IE IE2454/79A patent/IE48891B1/en unknown
- 1979-12-19 DK DK542279A patent/DK542279A/da not_active Application Discontinuation
- 1979-12-19 CH CH1127879A patent/CH641357A5/de not_active IP Right Cessation
- 1979-12-20 FI FI794007A patent/FI794007A7/fi not_active Application Discontinuation
- 1979-12-20 PT PT70619A patent/PT70619A/pt unknown
- 1979-12-21 BE BE0/198691A patent/BE880797A/fr not_active IP Right Cessation
- 1979-12-21 NO NO794252A patent/NO152726C/no unknown
- 1979-12-21 ES ES487181A patent/ES487181A0/es active Granted
- 1979-12-21 LU LU82026A patent/LU82026A1/fr unknown
- 1979-12-22 JP JP16632279A patent/JPS5587716A/ja active Pending
- 1979-12-24 GR GR60841A patent/GR69819B/el unknown

Also Published As

Publication number	Publication date
FI794007A7 (fi)	1981-01-01
NO152726C (no)	1985-11-13
DK542279A (da)	1980-06-23
SE7813246L (sv)	1980-06-23
BE880797A (fr)	1980-06-23
EP0013262B1 (en)	1983-08-03
ATE4370T1 (de)	1983-08-15
GR69819B (no)	1982-07-13
ZA796684B (en)	1980-11-26
IE792454L (en)	1980-06-22
AU531280B2 (en)	1983-08-18
IE48891B1 (en)	1985-06-12
CH641357A5 (de)	1984-02-29
NZ192441A (en)	1984-05-31
EP0013262A3 (en)	1981-05-27
EP0013262A2 (en)	1980-07-09
ES8101887A1 (es)	1980-12-16
ES487181A0 (es)	1980-12-16
NO152726B (no)	1985-08-05
DE2966036D1 (en)	1983-09-08
NO794252L (no)	1980-06-24
CA1130211A (en)	1982-08-24
JPS5587716A (en)	1980-07-02
AU5396379A (en)	1980-06-26
US4263273A (en)	1981-04-21
PT70619A (en)	1980-01-01

Publication	Publication Date	Title
LU82026A1 (fr)	1980-07-21	Preparation pharmaceutique comprenant un glycoside cardiaque ayant un revetement de polymere
EP2349227B1 (fr)	2018-05-30	Forme pharmaceutique orale a base de microgranules a liberation prolongee resistante a l'alcool
LU82025A1 (fr)	1980-07-21	Preparation pharmaceutique comprenant un glycoside cardiaque en combinaison avec un polymere
EP2605757B1 (fr)	2015-07-01	Formulations a base de nalbuphine et leurs utilisations
EP0300897B1 (fr)	1992-09-09	Dispositif à libération contrôlée qui fournit une délivrance continue d'un principe actif de manière contrôlée et compositions à particules multiples contenant de tels dispostifs
EP0624371A1 (fr)	1994-11-17	Microcapsules pour la libération contrôlée d'acide acétylsalicylique
FR2630912A1 (fr)	1989-11-10	Composition permettant d'administrer un medicament sous forme de gelules, d'une poudre ou d'un liquide
FR2613619A1 (fr)	1988-10-14	Medicaments, produits dietetiques ou produits d'hygiene sous forme de compositions pulverulentes obtenues par adsorption de principes actifs sur un sucre a dissolution rapide
CA2606887C (fr)	2014-07-15	Composition pharmaceutique
FR2930147A1 (fr)	2009-10-23	Forme orale solide dotee d'un double profil de liberation
WO2005004860A2 (fr)	2005-01-20	Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
FR2542194A1 (fr)	1984-09-14	Preparations pharmaceutiques a base de rifampicine ayant des proprietes d'elution uniformes
BE897221A (fr)	1984-01-05	Produits a effet prolonge contenant du suloctidil
CH629960A5 (fr)	1982-05-28	Composition pharmaceutique.
EP4313155A1 (fr)	2024-02-07	Formulation par voie orale d'ivermectine et utilisations
CN107737105A (zh)	2018-02-27	一种鼻腔用盐酸氮卓斯汀组合物喷雾剂及生产工艺
EP2294099A1 (fr)	2011-03-16	Forme galenique orale, procede de fabrication du polymere et utilisation
Gowthami et al.	2019	Formulation and evaluation of extended release pellets of pioglitazone hydrochloride using natural and synthetic polymers by fluidized bed coating technique
EP0412877A1 (fr)	1991-02-13	Nouvelle forme galénique orale améliorant la biodisponibilité
WO2023194433A1 (fr)	2023-10-12	Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales
EP4294383A1 (fr)	2023-12-27	Composition pour renforcer le systeme immunitaire
FR2715067A1 (fr)	1995-07-21	Nouvelle forme galénique de dérivés de 5-nitro-imidazole efficace pour le traitement des parasitoses et des infections de l'ensemble du tractus gastro-intestinal.
FR3143326A3 (fr)	2024-06-21	Composition pharmaceutique ou diététique comprenant un extrait de Hyphaene thebaica et un extrait d’Olea europaea utilisable comme un antihypertenseur et hypolipidémiant.
FR3013986A1 (fr)	2015-06-05	Composition pharmaceutique ou dietetique contenant l'extrait de semence d'avena sativa et utilisable pour soigner le syndrome metabolique
FR3108036A1 (fr)	2021-09-17	Composition pharmaceutique ou diététique contenant l’extrait aqueux de la lavande et utilisable comme antidiabétique